Participated · Seed · Mar 2026

VerbaFlo provides a purpose-built AI communications layer for residential real estate, deploying specialised AI agents across leasing, marketing, operations, and maintenance and integrating with existing property systems. The platform centralises conversations across email, web chat, messaging apps, and phone to enable real-time, multilingual engagement at scale. VerbaFlo aims to improve response times, increase conversion rates, and reduce operational workload for property operators. The company currently supports more than 200,000 units globally and has grown across the UK and Europe with recent expansion into the United States. Founded in 2024, VerbaFlo plans further international rollouts and continued product development funded by its recent seed raise. Its commercial positioning emphasises vertical-specific AI automation rather than general chatbot solutions.

Participated · Seed · Apr 2025

Neuranics develops ultra-sensitive, low-power, and scalable Tunnelling Magnetoresistance (TMR) magnetic sensors and associated custom circuitry and software to detect tiny magnetic signals from the human body without skin contact. Its sensors enable precise tracking of muscle activity for gesture recognition and detection of heart signals, targeting XR, wearables, and digital health applications. The company claims improved accuracy, reduced power consumption, and potential for continuous monitoring versus traditional methods. Neuranics is collaborating with Tier‑1 semiconductor and XR manufacturers to validate performance and production readiness for high-volume applications across consumer, industrial, and healthcare markets. Founded in 2021 as the first joint spinout from the University of Glasgow and the University of Edinburgh, the company has received recognition including a CES Innovation Award. With new funding, Neuranics plans to expand its team, accelerate core technology innovation, and drive integration of its TMR technology into emerging and high-tech markets. Neuranics is a Glasgow-based deep-tech spin-out from the Universities of Glasgow and Edinburgh that develops compact patented magnetic sensors and magnetomyography (MMG) technology for wearable wristbands. The company combines MMG with machine learning to detect muscle activity and interpret precise gestures. Initially it is targeting extended reality (XR) applications, with potential future use in healthcare, sports, gaming, and assistive technologies. Neuranics said an 18-month £2.4 million project, supported by an £800,000 grant from Scottish Enterprise, will fund R&D and create ten high-tech jobs at its Glasgow headquarters. The funding will support development of a compact wristband aimed at improving accuracy and comfort over existing gesture-recognition solutions. The company recently won a £125,000 fellowship grant from the Royal Commission for the Exhibition of 1851 and was awarded Deep Tech Investment of the Year at the UK Angel Investment Awards. Neuranics is a Glasgow-based sensor specialist founded in 2021 as a joint spinout from the University of Glasgow and the University of Edinburgh. The company develops magnetic sensors integrated with semiconductor technology using scalable spintronics sensors to detect tiny magnetic signals from organs such as the heart and muscles. Its patented technology is intended to address shortcomings in current health monitoring devices and human-machine interfaces. Neuranics’ magnetocardiography (MCG) sensors are described as easier to use than traditional electrocardiography (ECG) sensors, and its magnetomyography (MMG) system can estimate single finger movements by detecting magnetic activity in the forearm muscles. The sensors are said to improve latency when controlling robotic hands or interacting with virtual objects in the metaverse. The company raised £1.9M and intends to use the funds to expand operations and its business reach. The founders are Kia Nazarpour (CSO), Hadi Heidari (CTO), and Noel McKenna (CEO).

Participated · Equity · Feb 2025

uFraction8 develops microfluidics-based filtration systems that use hydrodynamic phenomena to provide a new mechanism of filtration for perfusion processes. Its technology is aimed at helping bio-manufacturers increase productivity with energy-efficient and scalable perfusion systems. The company targets industrial processes that use cell cultures to produce food, biopharmaceuticals and other bio-based products and chemicals. The technology was originally developed at the University of Edinburgh’s School of Engineering. uFraction8 is co-founded by Dr Brian Miller and Dr Monika Tomecka and currently employs seven people across Scotland and Poznan, Poland. The company intends to use recent funding to further commercialise its technology.

Participated · Equity · Sep 2024

Invizius is an Edinburgh-based biotech developing H-Guard, a surface-coating therapy flushed through dialysis machines to reduce the inflammatory response when patients' blood contacts machine surfaces. H-Guard aims to prevent immune reactions that can cause organ and cardiovascular damage in dialysis patients. A 'First in Human' study earlier this year demonstrated safety, tolerability and produced encouraging biomarker data. The new funding will support preparation for the next stage of clinical trials and the design of a trial for continuous renal replacement therapy (CRRT) to assess immune modulation and reduction of renal tubule damage. The company plans to advance into Phase 2B trials and continue research into additional patient benefits for H-Guard. Financially, the latest raise brings Invizius's total capital raised to over £13m. Invizius, based in Motherwell, Scotland, is a University of Edinburgh spin-out founded in 2017 and led by CEO Richard Boyd. The company is developing proprietary H-Guard® Priming Solution, a novel protein that lines the inside of the dialysis filter to prevent the blood’s foreign body response. Its core product aims to suppress unwanted innate immune responses and reduce the life-threatening inflammatory effects of haemodialysis. Invizius has established the regulatory pathway in North America and sees potential for coincident approval in Europe. The company intends to use the Series A funds to complete a First-in-Man safety study in 2022. It is also looking to expand its product pipeline into other high-value indications. Invizius is a University of Edinburgh spinout advancing dialysis technology to reduce cardiovascular risk in long-term dialysis patients. Its lead product, H-Guard™, is an anti-inflammatory 'primer' designed to coat filter surfaces so that when mixed with a patient's blood the surface appears less foreign to the immune system. The company plans to use the recent funds to build its team and advance the product toward the next stage of development ahead of clinical trials. The technology was developed from years of research by biologist Dr Andy Herbert (CTO) and his team, and the company is led by CEO Richard Boyd. Although the first application targets kidney dialysis, Invizius sees potential to apply the coating to other devices and procedures such as catheters, stents, organ transplants and vascular grafts. Invizius secured £500k from Mercia Fund Managers in the company's latest financing; the investment followed Mercia's partnership with the University of Edinburgh announced in November 2017.

Participated · Equity · Sep 2024

MiAlgae cultivates microalgae on by-products from whisky distillation to produce sustainable omega-3s for aquafeed, pet food and human health markets. Its NaturAlgae product is positioned as a drop-in omega-3 alternative to reduce reliance on wild fish. The company is based at Heriot-Watt University and launched a demonstrator site in 2023 that validated its technology at scale. MiAlgae is now preparing to develop an industrial-scale production facility in Scotland to fully commercialise NaturAlgae. The business recently secured £14 million in fresh funding to support that scale-up and to help create green jobs. Management says the investment will be used to build the infrastructure needed to meet growing global demand while continuing biotechnology innovation. MiAlgae, founded in 2016 and led by Managing Director Douglas Martin, applies biotechnology to produce a sustainable source of omega-3 for animal and human consumption. The company’s platform uses low-value coproducts from the food and drink industry as a feedstock to grow microalgae rich in omega-3 oils. MiAlgae is initially focused on the pet food sector with planned near-term expansion into aquaculture, the largest global consumer of fish oil. It also intends to commercialise other high-value compounds and pigments through expansion of its platform. The recently raised funds will be used to expand the team and complete a commercial demonstrator facility near Stirling to drive commercial traction. Financially, the company secured a £2.3M funding package from new and returning investors to support these commercialisation efforts. MiAlgae is a biotech company that produces microalgae using co-products from the whisky distillation process. The microalgae are high in omega-3 and other nutrients and can be used to sustainably feed fish and create animal food. The company targets the global aquaculture and pet food industries. MiAlgae plans to use the £1m funding to commercialize its product, double the size of its business premises, commission a demonstrator plant in East Lothian and make five new appointments in the next 12 months. The round was backed by Equity Gap, Scottish Investment Bank, Old College Capital and new investor Hillhouse Group. Founded by Douglas Martin in 2016 and based in Edinburgh, Scotland, the company intends to scale operations to serve international markets. MiAlgae produces a new kind of nutritious animal feed made from microalgae grown using co-products from Scotland’s whisky distillation process. The microalgae is rich in omega-3 and other vital nutrients and is aimed initially at the aquaculture industry. The company says the product is economical and environmentally friendly and can serve as an alternative raw material for agricultural feed. MiAlgae plans to use the new funding to scale and expand production capacity 30-fold, expand its team, and build a new plant at a whisky distillery. The company is led by founder Douglas Martin and is based in Scotland. The article does not report revenue or user metrics.